Search by Drug Name or NDC
NDC 61919-0279-30 ATENOLOL 25 mg/1 Details
ATENOLOL 25 mg/1
ATENOLOL is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Direct_Rx. The primary component is ATENOLOL.
MedlinePlus Drug Summary
Atenolol is used alone or in combination with other medications to treat high blood pressure. It also is used to prevent angina (chest pain) and improve survival after a heart attack. Atenolol is in a class of medications called beta blockers. It works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 61919-0279-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Atenolol
Product Information
| NDC | 61919-0279 |
|---|---|
| Product ID | 61919-279_0e881242-6142-027b-e063-6394a90ac8e2 |
| Associated GPIs | 33200020000303 |
| GCN Sequence Number | 015864 |
| GCN Sequence Number Description | atenolol TABLET 25 MG ORAL |
| HIC3 | J7C |
| HIC3 Description | BETA-ADRENERGIC BLOCKING AGENTS |
| GCN | 20662 |
| HICL Sequence Number | 002104 |
| HICL Sequence Number Description | ATENOLOL |
| Brand/Generic | Generic |
| Proprietary Name | ATENOLOL |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | ATENOLOL |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 25 |
| Active Ingredient Units | mg/1 |
| Substance Name | ATENOLOL |
| Labeler Name | Direct_Rx |
| Pharmaceutical Class | Adrenergic beta-Antagonists [MoA], beta-Adrenergic Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA074056 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 61919-0279-30 (61919027930)
| NDC Package Code | 61919-279-30 |
|---|---|
| Billing NDC | 61919027930 |
| Package | 30 TABLET in 1 BOTTLE (61919-279-30) |
| Marketing Start Date | 2019-09-17 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |